Unknown PHASE3 INTERVENTIONAL 2-arm NCT05040724

Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 (IVERCoV)

Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR

Sponsor: Raincy Montfermeil Hospital Group

Conditions To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care

Interventions Ivermectin

Updated 4 times since 2021 Last updated: Sep 9, 2021 Started: May 28, 2021 Primary completion: May 31, 2022 Completion: Jun 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care, this trial is ongoing. The trial is conducted by Raincy Montfermeil Hospital Group and has accumulated 4 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status
Oct 2021 — Jul 2023 [monthly]

Active Not Recruiting PHASE3

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Raincy Montfermeil Hospital Group

Data source: Raincy Montfermeil Hospital Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montfermeil, France